AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
|Articles|March 12, 2015
17-Year-Old with Recurring Rash (VIDEO)
This 17-year-old patient presents with discolored skin spots on the trunk; scales and peeling over lesions; chronic occurrence. Video from the Doctor's Channel.
Advertisement
Signs and Symptoms
This 17-year-old patient presents with discolored skin spots on the trunk; scales and peeling over lesions; chronic occurrence.
This video is from the Doctor's Channel.
This video is part of the
Advertisement
Related to this article
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
3
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
4
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
5